Trade Report: Today, Homrich & Berg decides to keep it stake in Vertex Pharmaceuticals Inc. (VRTX) to the level of $220,000

Today, Homrich & Berg decides to keep it stake in Vertex Pharmaceuticals Inc. (VRTX) to the level of $220,000

Homrich & Berg lowered its stake in Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) by 3.0% during the third quarter, Holdings Channel reports. The institutional investor owned 2,521 shares of the pharmaceutical company’s stock after selling 79 shares during the period. Homrich & Berg’s holdings in Vertex Pharmaceuticals were worth $220,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in VRTX. Citizens Financial Group Inc RI raised its position in shares of Vertex Pharmaceuticals by 27.0% in the second quarter. Citizens Financial Group Inc RI now owns 1,189 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 253 shares during the last quarter. Mycio Wealth Partners LLC raised its position in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 18 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at $107,000. Paradigm Asset Management Co. LLC raised its position in shares of Vertex Pharmaceuticals by 20.7% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,450 shares of the pharmaceutical company’s stock valued at $125,000 after buying an additional 249 shares during the last quarter. Finally, BlueMountain Capital Management LLC raised its position in shares of Vertex Pharmaceuticals by 69.3% in the first quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company’s stock valued at $148,000 after buying an additional 764 shares during the last quarter. 95.48% of the stock is currently owned by institutional investors.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded down 0.14% during midday trading on Friday, reaching $87.22. 451,966 shares of the company’s stock traded hands. Vertex Pharmaceuticals Inc. has a 52-week low of $73.31 and a 52-week high of $134.23. The stock’s 50 day moving average price is $83.90 and its 200 day moving average price is $89.83. The firm’s market capitalization is $21.63 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by $0.02. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The company earned $413.78 million during the quarter, compared to the consensus estimate of $423.53 million. During the same quarter last year, the company earned ($0.13) earnings per share. The business’s revenue was up 33.6% on a year-over-year basis. On average, equities research analysts anticipate that Vertex Pharmaceuticals Inc. will post $0.78 EPS for the current fiscal year.

Several research analysts have recently weighed in on VRTX shares. Jefferies Group reiterated a “buy” rating and set a $107.00 price objective (up from $102.00) on shares of Vertex Pharmaceuticals in a report on Sunday, July 31st. Morgan Stanley cut their price target on shares of Vertex Pharmaceuticals from $140.00 to $139.00 and set an “overweight” rating on the stock in a report on Thursday, July 28th. JMP Securities restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 16th. Leerink Swann set a $112.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, September 17th. Finally, RBC Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 12th. Sixteen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $108.13.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 5,062 shares of the company’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $90.98, for a total value of $460,540.76. Following the sale, the senior vice president now directly owns 17,125 shares in the company, valued at $1,558,032.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joshua S. Boger sold 6,500 shares of the company’s stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $95.66, for a total value of $621,790.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at $26,280,193.50. The disclosure for this sale can be found here. 1.90% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment